529 related articles for article (PubMed ID: 19804796)
1. kappa-Opioid receptor signaling and brain reward function.
Bruijnzeel AW
Brain Res Rev; 2009 Dec; 62(1):127-46. PubMed ID: 19804796
[TBL] [Abstract][Full Text] [Related]
2. Supersensitive Kappa Opioid Receptors Promotes Ethanol Withdrawal-Related Behaviors and Reduce Dopamine Signaling in the Nucleus Accumbens.
Rose JH; Karkhanis AN; Chen R; Gioia D; Lopez MF; Becker HC; McCool BA; Jones SR
Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26625893
[TBL] [Abstract][Full Text] [Related]
3. Dynorphin and κ-Opioid Receptor Dysregulation in the Dopaminergic Reward System of Human Alcoholics.
Bazov I; Sarkisyan D; Kononenko O; Watanabe H; Yakovleva T; Hansson AC; Sommer WH; Spanagel R; Bakalkin G
Mol Neurobiol; 2018 Aug; 55(8):7049-7061. PubMed ID: 29383684
[TBL] [Abstract][Full Text] [Related]
4. Dynorphin/Kappa Opioid Receptor Signaling in Preclinical Models of Alcohol, Drug, and Food Addiction.
Karkhanis A; Holleran KM; Jones SR
Int Rev Neurobiol; 2017; 136():53-88. PubMed ID: 29056156
[TBL] [Abstract][Full Text] [Related]
5. Addiction as a stress surfeit disorder.
Koob GF; Buck CL; Cohen A; Edwards S; Park PE; Schlosburg JE; Schmeichel B; Vendruscolo LF; Wade CL; Whitfield TW; George O
Neuropharmacology; 2014 Jan; 76 Pt B(0 0):370-82. PubMed ID: 23747571
[TBL] [Abstract][Full Text] [Related]
6. Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice.
Zhang Y; Butelman ER; Schlussman SD; Ho A; Kreek MJ
Psychopharmacology (Berl); 2004 Apr; 172(4):422-9. PubMed ID: 14712335
[TBL] [Abstract][Full Text] [Related]
7. Kappa-opioid receptor-dependent changes in dopamine and anxiety-like or approach-avoidance behavior occur differentially across the nucleus accumbens shell rostro-caudal axis.
Pirino BE; Spodnick MB; Gargiulo AT; Curtis GR; Barson JR; Karkhanis AN
Neuropharmacology; 2020 Dec; 181():108341. PubMed ID: 33011200
[TBL] [Abstract][Full Text] [Related]
8. Stress produces aversion and potentiates cocaine reward by releasing endogenous dynorphins in the ventral striatum to locally stimulate serotonin reuptake.
Schindler AG; Messinger DI; Smith JS; Shankar H; Gustin RM; Schattauer SS; Lemos JC; Chavkin NW; Hagan CE; Neumaier JF; Chavkin C
J Neurosci; 2012 Dec; 32(49):17582-96. PubMed ID: 23223282
[TBL] [Abstract][Full Text] [Related]
9. Nicotine withdrawal and kappa-opioid receptors.
McCarthy MJ; Zhang H; Neff NH; Hadjiconstantinou M
Psychopharmacology (Berl); 2010 Jun; 210(2):221-9. PubMed ID: 19806344
[TBL] [Abstract][Full Text] [Related]
10. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse.
Wee S; Koob GF
Psychopharmacology (Berl); 2010 Jun; 210(2):121-35. PubMed ID: 20352414
[TBL] [Abstract][Full Text] [Related]
11. Antireward, compulsivity, and addiction: seminal contributions of Dr. Athina Markou to motivational dysregulation in addiction.
Koob GF
Psychopharmacology (Berl); 2017 May; 234(9-10):1315-1332. PubMed ID: 28050629
[TBL] [Abstract][Full Text] [Related]
12. A review of the kappa opioid receptor system in opioid use.
Cayir S; Zhornitsky S; Barzegary A; Sotomayor-Carreño E; Sarfo-Ansah W; Funaro MC; Matuskey D; Angarita G
Neurosci Biobehav Rev; 2024 Jul; 162():105713. PubMed ID: 38733895
[TBL] [Abstract][Full Text] [Related]
13. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions.
Kreek MJ; Schluger J; Borg L; Gunduz M; Ho A
J Pharmacol Exp Ther; 1999 Jan; 288(1):260-9. PubMed ID: 9862779
[TBL] [Abstract][Full Text] [Related]
14. Ginsenoside Re protects methamphetamine-induced dopaminergic neurotoxicity in mice via upregulation of dynorphin-mediated κ-opioid receptor and downregulation of substance P-mediated neurokinin 1 receptor.
Dang DK; Shin EJ; Kim DJ; Tran HQ; Jeong JH; Jang CG; Nah SY; Jeong JH; Byun JK; Ko SK; Bing G; Hong JS; Kim HC
J Neuroinflammation; 2018 Feb; 15(1):52. PubMed ID: 29467000
[TBL] [Abstract][Full Text] [Related]
15. Effects of Kappa opioid receptor blockade by LY2444296 HCl, a selective short-acting antagonist, during chronic extended access cocaine self-administration and re-exposure in rat.
Valenza M; Windisch KA; Butelman ER; Reed B; Kreek MJ
Psychopharmacology (Berl); 2020 Apr; 237(4):1147-1160. PubMed ID: 31915862
[TBL] [Abstract][Full Text] [Related]
16. Differential time course of effects of kappa-opioid agonist treatment on dynorphin A levels and kappa-opioid receptor density.
D'Addario C; Di Benedetto M; Izenwasser S; Candeletti S; Romualdi P
J Mol Neurosci; 2004; 24(2):307-14. PubMed ID: 15456944
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of dynorphin/kappa opioid receptor system in the dorsal hippocampus contributes to morphine withdrawal-induced place aversion.
Chen Y; Wang CY; Zan GY; Yao SY; Deng YZ; Shu XL; Wu WW; Ma Y; Wang YJ; Yu CX; Liu JG
Acta Pharmacol Sin; 2023 Mar; 44(3):538-545. PubMed ID: 36127507
[TBL] [Abstract][Full Text] [Related]
18. A ghrelin receptor (GHS-R1A) antagonist attenuates the rewarding properties of morphine and increases opioid peptide levels in reward areas in mice.
Engel JA; Nylander I; Jerlhag E
Eur Neuropsychopharmacol; 2015 Dec; 25(12):2364-71. PubMed ID: 26508707
[TBL] [Abstract][Full Text] [Related]
19. Nicotine and endogenous opioids: neurochemical and pharmacological evidence.
Hadjiconstantinou M; Neff NH
Neuropharmacology; 2011 Jun; 60(7-8):1209-20. PubMed ID: 21108953
[TBL] [Abstract][Full Text] [Related]
20. Brain site-specific regulation of hedonic intake by orexin and DYN peptides: role of the PVN and obesity.
Mattar P; Uribe-Cerda S; Pezoa C; Guarnieri T; Kotz CM; Teske JA; Morselli E; Perez-Leighton C
Nutr Neurosci; 2022 May; 25(5):1105-1114. PubMed ID: 33151127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
